Carina Biotech
Stephen Livesey is currently serving as a Board Member in multiple biotech companies, including Carina Biotech, TekCyte, and CureCell. Stephen is the CEO of BioVictus Pty Ltd and has been working as a Scientist at Clinical Neurosciences SVHM. With a background in Biological Science and Medicine, Stephen has held various executive positions in the biotech industry, including CEO and CSO at Australian Stem Cell Centre and Executive VP and CSO at LifeCell Corporation. Stephen is also a co-founder and inventor of platform technologies and products AlloDerm and Cymetra.
Carina Biotech
Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing. We are working to… 1. Expand the clinical indications for T cell therapies 2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Women's & Children's Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Children's Hospital in the United States.